Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Olorofim in Healthy Subjects
NCT03340597Phase 1Completed
- Sponsor
- F2G
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive aspergillosis (IA) (4 arms), sponsored by F2G. Primary endpoint: Incidence of treatment emergent adverse events at 18 days. Started Dec 2017; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03340597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340597.